Clinical Trials Logo

Filter by:
NCT ID: NCT05225831 Recruiting - Clinical trials for CD19+ and CD 22+ B-ALL

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Start date: August 15, 2021
Phase: Early Phase 1
Study type: Interventional

This is an open, single-arm, prospective clinical study to evaluate the safety and efficacy of anti CD19 and CD22 CAR-T cell in the treatment of R/R B-ALL.

NCT ID: NCT05225116 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Start date: January 8, 2023
Phase: Phase 1
Study type: Interventional

Patients with hepatocellular carcinoma with PVTT can benefit from surgical resection and radiotherapy. As the rapid development of systematic treatment in hepatocellular carcinoma, ICIs neoadjuvant therapy is being actively explored .But there is no evidence to prove the safety and efficacy of lenvatinib and anti-PD1 antibody combined with radiotherapy neoadjuvant treatment for resectable hepatocellular carcinoma with PVTT. This study intends to supplement the evidence of benefit in such patients.

NCT ID: NCT05224934 Recruiting - Soft Tissue Sarcoma Clinical Trials

Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma

NCT ID: NCT05224596 Recruiting - Cancer Clinical Trials

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-Gastric

ASCEND-Gastric
Start date: January 18, 2021
Phase:
Study type: Observational

ASCEND-Gastric is a prospective, multi-omics, observational study aimed at detecting gastric cancer by combined assays for serum protein markers, deep sequencing of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA) mutation and circulating RNA. The study will enroll 498 participants, including 128 patients with benign gastric diseases and 370 patients with gastric cancer.

NCT ID: NCT05223894 Recruiting - Heart Failure Clinical Trials

Treating Heart Failure With hiPSC-CMs

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes. Cellular replacement therapy is a potential approach to repair damaged myocardial tissue, restore cardiac function, which has become a new strategy for the treatment of heart failure. The purpose of this study is to assess the safety and efficacy of intramyocardial delivery of cardiomyocytes at the time of coronary artery bypass grafting in patients with chronic heart failure.

NCT ID: NCT05223712 Recruiting - Kidney Diseases Clinical Trials

Artificial Intelligence System for the Detection and Prediction of Kidney Diseases Using Ocular Information

Start date: August 28, 2021
Phase:
Study type: Observational

This is an retrospective and prospective multicenter study to develop and validate an artificial intelligent (AI) aided diagnosis, therapeutic effect assessment model including chronic kidney disease (CKD) and dialysis patients starting from April 2009, which is based on ophthalmic examinations (e.g. retinal fundus photography, slit-lamp images, OCTA, etc.) and CKD diagnostic and therapeutic data (routine clinical evaluations and laboratory data), to provide a reliable basis and guideline for clinical diagnosis and treatment.

NCT ID: NCT05223595 Recruiting - Clinical trials for Metastatic Non-Small Cell Lung Cancer

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Start date: April 2, 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, multicenter, open label study to investigate the safety and efficacy of Gentuximab plus Almonertinib in metastatic NSCLC patients with EGFR mutation-positive.

NCT ID: NCT05223569 Recruiting - Clinical trials for Macular Edema Due to Diabetes Mellitus

Home Monitoring of Diabetic Macular Edema

Start date: March 3, 2022
Phase: N/A
Study type: Interventional

Diabetic macular edema (DME) is part of diabetic retinopathy (DR) and a leading cause of central visual loss in people with diabetes . Most patients require pharmacological inhibition using anti-vascular endothelial growth factor (VEGF) agents with multiple monitoring visits that include optical coherence tomography (OCT), visual acuity test, and multiple injections.The substantial visit frequency puts pressure on ophthalmic clinics, and can impose a tremendous burden on both patients and their caregivers. Therefore, self-service examination instruments that can be portable and fast-moving become the key for realizing tele-medicine. Recently, the investigators have developed a portable, self-administrated home OCT machine, which is designed for home-based OCT scanning and monitoring for patients with retinal diseases including DME, age related macular degeneration (AMD) and choroidal neovascularization (CNV) that require multiple anti-VEGF injections. The investigators have confirmed its image quality and validated the retinal thickness measurements obtained from this device by comparing with hospital OCT (staff-administrated and clinic-based).In this study, the investigators will conduct a randomized clinical trial (RCT) to compare the efficacy and cost-effectiveness of a home OCT monitoring model versus standard hospital care model for patients with diabetic macular edema who need anti-VEGF injections.

NCT ID: NCT05223517 Recruiting - Clinical trials for Acupuncture, Chronic Pelvic Pain, Woman

Acupuncture for Chronic Pelvic Pain

Start date: March 6, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to assess the effects and safety of acupuncture for moderate to severe chronic pelvic pain in women.

NCT ID: NCT05223231 Recruiting - Clinical trials for Advanced Malignant Tumors

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Start date: February 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1 antibody in patients with advanced malignant tumors.